NEW YORK (GenomeWeb) – Ncardia said today that it has entered into a non-exclusive global intellectual property licensing agreement with Evotec, which gives Evotec access to patented technology and methods for stem cell-derived modeling for target discovery, drug efficacy, and safety testing.

Ncardia has developed a variety of predictive human cellular assays systems, including a broad panel of induced pluripotent stem cell (iPSC)-derived lines of both cardiac cells and neurons.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.